DYN Stock: Price, Earnings History and SEC Filings
Dyne Therapeutics, Inc. (DYN) last traded at $16.69, down 2.05% on the latest session and up 3.6% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.08 against an analyst estimate of $-0.74, a miss of 45.9%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
DYN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 29, 2026 | $-1.08 | $-0.74 | -45.95% |
| Mar 2026 | May 11, 2026 | $-0.73 | $-0.74 | +1.35% |
| Dec 2025 | Mar 2, 2026 | $-0.76 | $-0.74 | -2.70% |
| Sep 2025 | Nov 5, 2025 | $-0.76 | $-0.81 | +6.17% |
DYN beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How DYN reacts to earnings
Across its last 8 earnings releases, DYN moved 6.4% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-07-29 | After close | +2.51% |
| 2026-05-11 | Before open | +4.83% |
| 2026-03-02 | Before open | +3.39% |
| 2026-01-12 | Before open | -1.74% |
| 2025-11-05 | After close | -12.89% |
| 2025-07-28 | After close | -1.18% |
| 2025-05-08 | Before open | +20.16% |
| 2025-02-27 | Before open | -4.50% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
DYN financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | – | -$446M | -$405M | – | $-3.47 |
| 2024 | – | -$317M | -$295M | – | $-3.37 |
| 2023 | – | -$236M | -$189M | – | $-3.95 |
| 2022 | – | -$168M | -$157M | – | $-3.23 |
| 2021 | – | -$149M | -$123M | – | $-2.93 |
| 2020 | – | -$59M | -$48M | – | – |
| 2019 | – | -$15M | -$13M | – | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for DYN
- 8-K · Sep 29, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Jul 29, 2026Results of operations, Financial statements and exhibits
- 10-Q · Jul 29, 2026
- 424B5 · Jul 22, 2026
- 8-K · Jul 22, 2026Material agreement, Other events, Financial statements and exhibits
- 424B5 · Jul 21, 2026
- 8-K · Jul 20, 2026Other events
- 8-K · Jun 22, 2026Officer or director change
- 8-K · Jun 17, 2026Material agreement, New financial obligation
- 8-K · Jun 8, 2026Shareholder vote
Insider filing activity
DYN insiders filed 10 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
DYN news
- Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Oct 22, 2026 · finance.yahoo.com
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. (DYN) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.